ESTRO 2023 - Abstract Book

S1268

Digital Posters

ESTRO 2023

Treatment in 3 patients was multimodal by surgery, chemotherapy (CT) and Radiotherapy (RT), one patient was treated with palliative CT and another with surgery alone. After a median follow-up of 24 months, 2 patients died cancer-specific (40%) with a median of 16 months since diagnosis (range 11-21). Currently 3 patients are alive with stable disease after a median follow-up of 34 months (range 24-52). A statistically significant association was found between stage and death (p=0.025) as well as time between RT and RIS, and death (p= 0.009). Multimodal treatment is associated statistically significant differences with longer follow- up time (p=0.041). Conclusion The results from this review on 5 patients suggest that the addition of reirradiation to surgery and chemotherapy – multimodal approach - might be benefit for the local control of RIS. However, it warrants further investigation and a larger number of patients. M. Árquez Pianetta 1 , M. Arguís Pinel 1 , A. Ejimeno Castejín 2 , D. Gómez Gómez 1 , M. Murcia 1 , F.A. Castaño Zuleta 1 , Y. López 1 , J. Trilla 1 , B. Malavé Chacón 1 , D. Calderón 1 , L. Torres Royo 3 , C. Escuin Troncho 1 , O. Engel 1 , A. Santafé 1 , P. Araguás Mora 1 , J. Acosta Arteaga 1 , F. Reventóz Martínez 4 , M. Arenas Prat 1 1 University Hospital Sant Joan of Reus, Radiation Oncology, Reus, Spain; 2 Rovira i Virgili University, Medicine, Tarragona, Spain; 3 Cork University Hospital, Radiation Oncology, Cork, Ireland; 4 Institut Catalá de Salut, ABS Balaguer, Lleida, Spain Purpose or Objective To demonstrate that external radiotherapy with Electron beam (EB), brachytherapy HDR (HDR) and orthovoltage (OV) are excellent treatments for NMSC, with good response, tolerance and low acute and chronic toxicity. Materials and Methods A retrospective and descriptive study were carried out on 300 patients with a histological diagnosis of NMSC, treated with external at the Hospital Universitario Sant Joan de Reus between 2003 and 2019. Acute and chronic toxicity, response to treatment, recurrence and other variables were analysed. PO-1562 Radiotherapy treatment in non melanoma skin cancer (NMSC) The mean age at diagnosis was 78.6 years (30-102 years). The most frequent histology was basal cell skin cancer (BCC) with 167 (55.7%) and 128 squamous cell skin cancer (SCC) (42.7%). The median follow-up was 72 months (0 - 175 months). In relation to the histological grade, grade II was the most frequent (51%). Infiltration was present in 5.3% of cases. The margins were affected in 69.7% of cases. 79.9% of cases were recent occurrence tumours, mostly located in the H zone (49.2%) and with a T1 tumour stage (58.6%). In 63.7% of cases. 100 patients (33.3%) were treated with EB, 100 (33.3%) with HDR and the remaining 100 (33.3%) with OV. The dose administered ranged from 30 to 70Gy, with fractions from 1.8 to 4.5Gy. In 202 patients (67.3%), the intention was radical, and 98 (32.7%) adjuvant to surgery In radically treated patients, complete response was obtained in 94.56%, partial response: 2.47% and persistence of the disease: 2.97%. 1.4% of cases died due to disease, 0.3% are alive with disease, 27.3% alive without disease and 71% of the patients analysed died from causes other than NMSC. Statistically significant association was found between the occurrence of toxicity and the type of radiotherapy used. Results 63.7% of patients were men. The functional state was ECOG 1 in 63% of cases.

Acute toxicity: Grade 4: 4.3%, Grade 3: 38.3%, Grade 2: 40.3% and Grade 1: 16.7%.

Late toxicity: Grade 4: 4.2%, Grade 3: 0.8%, Grade 2: 6.1%, Grade 1: 37.4% and Grade 0: 51.5%.

Conclusion External radiotherapy with its different techniques (Orthovoltage, photons and electrons) is a excellent alternative in patients with NMSC, with Good control and cosmetic.

PO-1563 The role of postoperative radiotherapy in uterine sarcomas: a single institution analysis.

M. Cerrolaza 1 , A. Mendez 1 , V. Navarro 1 , A. Lanuza 1 , A. Miranda 2 , A. Campos 1 , M. Gascon 3 , J.M. Ponce 4 , R. Ibañez 4

1 University Hospital Miguel Servet , Radiation Oncology, ZARAGOZA, Spain; 2 National Oncological Institute "Dr. Juan Tanca Marengo" (SOLCA), Radiation Oncology, Guayaquil, Ecuador; 3 University Clinical Hospital Lozano Blesa, Radiation Oncology, ZARAGOZA, Spain; 4 University Hospital Miguel Servet, Radiation Oncology, ZARAGOZA, Spain Purpose or Objective Uterine sarcomas (US) are rare malignant tumours arising from the smooth muscle or connective tissue of the uterus which account for only 3 to 7% of uterine malignancies but are the most common cause of uterine cancer-specific death. The most represented histological subtypes are leiomyosarcoma (LMS), endometrial stromal sarcoma (ESS), adenosarcoma (AS) and undifferentiated uterine sarcoma (USS). Uterine carcinosarcoma has been excluded from US classification as considering biphasic neoplasms (epithelial and mesenchymal elements), a subtype of high-grade endometrial sarcomas. The present